Parkinson’s disease is a common, adult-onset neurodegenerative disorder whose pathogenesis is still under intense investigation. Substantial evidence from postmortem human brain tissue, genetic- and toxin-induced animal and cellular models indicates that mitochondrial dysfunction plays a central role in the pathophysiology of the disease. This review discusses our current understanding of Parkinson’s disease–related mitochondrial dysfunction, including bioenergetic defects, mitochondrial DNA alterations, altered mitochondrial dynamics, activation of mitochondrial-dependent programmed cell death, and perturbations in mitochondrial tethering to the endoplasmic reticulum. Whether a primary or secondary event, mitochondrial dysfunction holds promise as a potential therapeutic target to halt the progression of neurodegeneration in Parkinson’s disease.
AndrabiSADawsonTMDawsonVL. 2008. Mitochondrial and nuclear cross talk in cell death: parthanatos. Ann N Y Acad Sci1147:233–41.
2.
Andres-MateosEPerierCZhangLBlanchard-FillionBGrecoTMThomasB, and others. 2007. DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. Proc Natl Acad Sci U S A104:14807–12.
3.
AngladeP. 1997. Apoptosis and autophagy in nigral neurons of patients with Parkinson’s disease. Histol Histopathol12:25–31.
4.
BenderAKrishnanKJMorrisCMTaylorGAReeveAKPerryRH, and others. 2006. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet38:515–7.
5.
BernhardWRouillerC. 1956. Close topographical relationship between mitochondria and ergastoplasm of liver cells in a definite phase of cellular activity. J Biophys Biochem Cytol2:73–8.
6.
BerthetAMargolisEBZhangJHsiehIZhangJHnaskoTS, and others. 2014. Loss of mitochondrial fission depletes axonal mitochondria in midbrain dopamine neurons. J Neurosci34:14304–17.
7.
BetarbetRShererTBMackenzieGGarcia-OsunaMPanovAVGreenamyreJT. 2000. Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat Neurosci3:1301–6.
8.
BonifatiVRizzuPvan BarenMJSchaapOBreedveldGJKriegerE, and others. 2003. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science299:256–9.
9.
BüttnerSHabernigLBroeskampFRuliDVögtleFNVlachosM, and others. 2013. Endonuclease G mediates α-synuclein cytotoxicity during Parkinson’s disease. EMBO J32:3041–54.
ChanCSGuzmanJNIlijicEMercerJNRickCTkatchT, and others. 2007. “Rejuvenation” protects neurons in mouse models of Parkinson’s disease. Nature447:1081–6.
12.
ChangDTWHonickASReynoldsIJ. 2006. Mitochondrial trafficking to synapses in cultured primary cortical neurons. J Neurosci26:7035–45.
13.
CharanRAJohnsonBNZaganelliSNardozziJDLaVoieMJ. 2014. Inhibition of apoptotic Bax translocation to the mitochondria is a central function of parkin. Cell Death Dis5:e1313.
CironCLengacherSDusonchetJAebischerPSchneiderBL. 2012. Sustained expression of PGC-1α in the rat nigrostriatal system selectively impairs dopaminergic function. Hum Mol Genet21:1861–76.
16.
DaiYClarkJZhengKKujothGCProllaTASimonDK. 2014. Somatic mitochondrial DNA mutations do not increase neuronal vulnerability to MPTP in young POLG mutator mice. Neurotoxicol Teratol46C:62–7.
17.
DariosFCortiOLückingCBHampeCMurielM-PAbbasN, and others. 2003. Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. Hum Mol Genet12:517–26.
18.
DauerWPrzedborskiS. 2003. Parkinson’s disease: mechanisms and models. Neuron39:889–909.
19.
DaveyGPClarkJB. 1996. Threshold effects and control of oxidative phosphorylation in nonsynaptic rat brain mitochondria. J Neurochem66:1617–24.
20.
de BritoOMScorranoL. 2008. Mitofusin 2 tethers endoplasmic reticulum to mitochondria. Nature456:605–10.
21.
DehayBMartinez-VicenteMCaldwellGACaldwellKAYueZCooksonMR, and others. 2013. Lysosomal impairment in Parkinson’s disease. Mov Disord28:725–32.
22.
DentonRM. 2009. Regulation of mitochondrial dehydrogenases by calcium ions. Biochim Biophys Acta1787:1309–16.
23.
DetmerSAChanDC. 2007. Functions and dysfunctions of mitochondrial dynamics. Nat Rev Mol Cell Biol8:870–9.
24.
EkstrandMITerziogluMGalterDZhuSHofstetterCLindqvistE, and others. 2007. Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons. Proc Natl Acad Sci U S A104:1325–30.
25.
EschbachJvon EinemBMüllerKBayerHScheffoldAMorrisonBE, and others. 2015. Mutual exacerbation of PGC-1α deregulation and α-synuclein oligomerization. Ann Neurol77:15–32.
26.
FrezzaCCipolatSMartins de BritoOMicaroniMBeznoussenkoGVRudkaT, and others. 2006. OPA1 controls apoptotic cristae remodeling independently from mitochondrial fusion. Cell126:177–89.
27.
Guardia-LaguartaCArea-GomezERübCLiuYMagranéJBeckerD, and others. 2014. α-Synuclein is localized to mitochondria-associated ER membranes. J Neurosci34:249–59.
28.
HattoriNTanakaMOzawaTMizunoY. 1991. Immunohistochemical studies on complexes I, II, III, and IV of mitochondria in Parkinson’s disease. Ann Neurol30:563–71.
29.
HudsonGNallsMEvansJRBreenDPWinder-RhodesSMorrisonKE, and others. 2013. Two-stage association study and meta-analysis of mitochondrial DNA variants in Parkinson disease. Neurology80:2042–8.
IrrcherIAleyasinHSeifertELHewittSJChhabraSPhillipsM, and others. 2010. Loss of the Parkinson’s disease-linked gene DJ-1 perturbs mitochondrial dynamics. Hum Mol Genet19:3734–46.
32.
KeeneyPMXieJCapaldiRABennettJP. 2006. Parkinson’s disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J Neurosci26:5256–64.
33.
KrebiehlGRuckerbauerSBurbullaLFKieperNMaurerBWaakJ, and others. 2010. Reduced basal autophagy and impaired mitochondrial dynamics due to loss of Parkinson’s disease-associated protein DJ-1. PLoS One5:e9367.
34.
KujothGCHionaAPughTDSomeyaSPanzerKWohlgemuthSE, and others. 2005. Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging. Science309:481–4.
35.
LangstonJWBallardPTetrudJWIrwinI. 1983. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science219:979–80.
36.
LemastersJJ. 2005. Selective mitochondrial autophagy, or mitophagy, as a targeted defense against oxidative stress, mitochondrial dysfunction, and aging. Rejuvenation Res8:3–5.
37.
LoebVYakuninESaadaASharonR. 2010. The transgenic overexpression of α-synuclein and not its related pathology associates with complex I inhibition. J Biol Chem285:7334–43.
38.
MandirASPrzedborskiSJackson-LewisVWangZQSimbulan-RosenthalCMSmulsonME, and others. 1999. Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. Proc Natl Acad Sci U S A96:5774–9.
39.
MartinatCShendelmanSJonasonALeeteTBealMFYangL, and others. 2004. Sensitivity to oxidative stress in DJ-1-deficient dopamine neurons: an ES-derived cell model of primary Parkinsonism. PLoS Biol2:e327.
40.
MudòGMäkeläJDi LibertoVTselykhT VOlivieriMPiepponenP, and others. 2012. Transgenic expression and activation of PGC-1α protect dopaminergic neurons in the MPTP mouse model of Parkinson’s disease. Cell Mol Life Sci69:1153–65.
41.
OttoliniDCalìTNegroABriniM. 2013. The Parkinson disease-related protein DJ-1 counteracts mitochondrial impairment induced by the tumour suppressor protein p53 by enhancing endoplasmic reticulum–mitochondria tethering. Hum Mol Genet22:2152–68.
42.
ParkerWDBoysonSJParksJK. 1989. Abnormalities of the electron transport chain in idiopathic Parkinson’s disease. Ann Neurol26:719–23.
43.
PerierCBenderAGarcía-ArumíEMeliàMJBovéJLaubC, and others. 2013. Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms. Brain136:2369–78.
44.
PerierCBovéJDehayBJackson-LewisVRabinovitchPSPrzedborskiS, and others. 2010. Apoptosis-inducing factor deficiency sensitizes dopaminergic neurons to parkinsonian neurotoxins. Ann Neurol68:184–92.
45.
PerierCBovéJVilaM. 2012. Mitochondria and programmed cell death in Parkinson’s disease: apoptosis and beyond. Antioxid Redox Signal16:883–95.
46.
PerierCBovéJWuD-CDehayBChoiD-KJackson-LewisV, and others. 2007. Two molecular pathways initiate mitochondria-dependent dopaminergic neurode-generation in experimental Parkinson’s disease. Proc Natl Acad Sci U S A104:8161–6.
47.
PerierCTieuKGuéganCCaspersenCJackson-LewisVCarelliV, and others. 2005. Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage. Proc Natl Acad Sci U S A102:19126–31.
48.
PerierCVilaM. 2012. Mitochondrial biology and Parkinson’s disease. Cold Spring Harb Perspect Med2:a009332.
49.
PickrellAMPintoMHidaAMoraesCT. 2011. Striatal dysfunctions associated with mitochondrial DNA damage in dopaminergic neurons in a mouse model of Parkinson’s disease. J Neurosci31:17649–58.
50.
RakovicAShurkewitschKSeiblerPGrünewaldAZanonAHagenahJ, and others. 2013. Phosphatase and tensin homolog (PTEN)-induced putative kinase 1 (PINK1)-dependent ubiquitination of endogenous Parkin attenuates mitophagy: study in human primary fibroblasts and induced pluripotent stem cell-derived neurons. J Biol Chem288:2223–37.
51.
RamonetDPerierCRecasensADehayBBovéJCostaV, and others. 2013. Optic atrophy 1 mediates mitochondria remodeling and dopaminergic neurodegeneration linked to complex I deficiency. Cell Death Differ20:77–85.
52.
RaoVKCarlsonEAYanSS. 2014. Mitochondrial permeability transition pore is a potential drug target for neurodegeneration. Biochim Biophys Acta1842:1267–72.
53.
RappoldPMCuiMGrimaJCFanRZde Mesy-BentleyKLChenL, and others. 2014. Drp1 inhibition attenuates neurotoxicity and dopamine release deficits in vivo. Nat Commun5:5244.
54.
ReeveAMeagherMLaxNSimcoxEHepplewhitePJarosE, and others. 2013. The impact of pathogenic mitochondrial DNA mutations on substantia nigra neurons. J Neurosci33:10790–801.
55.
SandersLHMcCoyJHuXMastroberardinoPGDickinsonBCChangCJ, and others. 2014. Mitochondrial DNA damage: molecular marker of vulnerable nigral neurons in Parkinson’s disease. Neurobiol Dis70:214–23.
56.
SantosDCardosoSM. 2012. Mitochondrial dynamics and neuronal fate in Parkinson’s disease. Mitochondrion12:428–37.
57.
ScarffeLAStevensDADawsonVLDawsonTM. 2014. Parkin and PINK1: much more than mitophagy. Trends Neurosci37:315–24.
58.
SchapiraAHCooperJMDexterDClarkJBJennerPMarsdenCD. 1990. Mitochondrial complex I deficiency in Parkinson’s disease. J Neurochem54:823–7.
59.
StefanisL. 2012. α-Synuclein in Parkinson’s disease. Cold Spring Harb Perspect Med2:a009399.
60.
St-PierreJDroriSUldryMSilvaggiJMRheeJJägerS, and others. 2006. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell127:397–408.
61.
SzabadkaiGBianchiKVárnaiPDe StefaniDWieckowskiMRCavagnaD, and others. 2006. Chaperone-mediated coupling of endoplasmic reticulum and mitochondrial Ca2+ channels. J Cell Biol175:901–11.
TwigGShirihaiOS. 2011. The interplay between mitochondrial dynamics and mitophagy. Antioxid Redox Signal14:1939–51.
64.
VanceJE. 2014. MAM (mitochondria-associated membranes) in mammalian cells: lipids and beyond. Biochim Biophys Acta1841:595–609.
65.
VenderovaKParkDS. 2012. Programmed cell death in Parkinson’s disease. Cold Spring Harb Perspect Med2:a009365.
66.
Vives-BauzaCPrzedborskiS. 2011. Mitophagy: the latest problem for Parkinson’s disease. Trends Mol Med17:158–65.
67.
WangH-LChouA-HYehT-HLiAHChenY-LKuoY-L, and others. 2007. PINK1 mutants associated with recessive Parkinson’s disease are defective in inhibiting mitochondrial release of cytochrome c. Neurobiol Dis28:216–26.
68.
WangYDawsonVLDawsonTM. 2009. Poly(ADP-ribose) signals to mitochondrial AIF: a key event in parthanatos. Exp Neurol218:193–202.
69.
YouleRJNarendraDP. 2011. Mechanisms of mitophagy. Nat Rev Mol Cell Biol12:9–14.
70.
ZhengBLiaoZLocascioJJLesniakKA.RoderickSSWattML, and others. 2010. PGC-1α, a potential therapeutic target for early intervention in Parkinson’s disease. Sci Transl Med2:52ra73.
